Primary biological screening of photosensitizers for photodynamic activity on a nontumor model in vivo

1992 ◽  
Vol 114 (6) ◽  
pp. 1873-1877
Author(s):  
V. E. Normanskii ◽  
N. T. Raikhlin
2019 ◽  
Vol 163 ◽  
pp. 779-786 ◽  
Author(s):  
Zhao Zhang ◽  
Hua-Jun Yu ◽  
Hui Huang ◽  
Hua-Hua Wang ◽  
Shang Wu ◽  
...  

1994 ◽  
Vol 69 (5) ◽  
pp. 840-845 ◽  
Author(s):  
HLLM van Leengoed ◽  
V Cuomo ◽  
AAC Versteeg ◽  
N van der Veen ◽  
G Jori ◽  
...  

2009 ◽  
Vol 52 (14) ◽  
pp. 4306-4318 ◽  
Author(s):  
Xiang Zheng ◽  
Janet Morgan ◽  
Suresh K. Pandey ◽  
Yihui Chen ◽  
Erin Tracy ◽  
...  

2020 ◽  
Author(s):  
Sam Benson ◽  
Fabio de Moliner ◽  
Antonio Fernandez ◽  
Erkin Kuru ◽  
Nicholas Asiimwe ◽  
...  

Photoactivatable molecules enable ablation of malignant cells under the control of light, yet current agents can be ineffective at early stages of disease when target cells are similar to healthy surrounding tissues. In this work, we describe a chemical platform based on amino-substituted benzoselenadiazoles to build photosensitizers that mimic native metabolites as indicators of disease onset and progression. Through a series of synthetic derivatives, we have identified the key chemical groups in the benzoselenadiazole scaffold responsible for its photodynamic activity, and subsequently designed photosensitive metabolic warheads to target cells associated with various diseases, including bacterial infections and cancer. We demonstrate that versatile benzoselenadiazole metabolites can selectively kill pathogenic cells -but not healthy cells- with high precision after exposure to non-toxic visible light, reducing any potential side effects in vivo. This chemical platform provides powerful new tools to exploit cellular metabolic signatures for safer therapeutic and surgical approaches. <br>


1992 ◽  
Vol 55 (1) ◽  
pp. 133-136 ◽  
Author(s):  
Alan R. Morgan ◽  
Dimitris Skalkos ◽  
George Maguire ◽  
Ashraf Rampersaud ◽  
Greta Garbo ◽  
...  

2004 ◽  
Vol 286 (1-2) ◽  
pp. 131-145 ◽  
Author(s):  
Angelica Vargas ◽  
Bernadette Pegaz ◽  
Elodie Debefve ◽  
Yvette Konan-Kouakou ◽  
Norbert Lange ◽  
...  

Pharmaceutics ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 676
Author(s):  
Marie Millard ◽  
Solène Posty ◽  
Max Piffoux ◽  
Jordane Jasniewski ◽  
Henri-Pierre Lassalle ◽  
...  

Extracellular vesicles (EVs), derived from the cell, display a phospholipid bilayer membrane that protects the cargo molecules from degradation and contributes to increasing their stability in the bloodstream and tumor targeting. EVs are interesting in regard to the delivery of photosensitizers (PSs) used in the photodynamic therapy (PDT), as they allow us to overcome the limitations observed with liposomes. In fact, liposomal formulation of meta-tetra(hydroxyphenyl)chlorin (mTHPC) (Foslip®), one of the most potent clinically approved PSs, is rapidly destroyed in circulation, thus decreasing in vivo PDT efficacy. mTHPC-EV uptake was evaluated in vitro in a 3D human colon HT-29 microtumor and in vivo study was performed in HT-29 xenografted mice. The obtained data were compared with Foslip®. After intravenous injection of the mTHPC formulations, biodistribution, pharmacokinetics and PDT-induced tumor regrowth were evaluated. In a 3D model of cells, mTHPC-EV uptake featured a deeper penetration after 24h incubation compared to liposomal mTHPC. In vivo results showed a considerable improvement of 33% tumor cure with PDT treatment applied 24h after injection, while 0% was observed after Foslip®/PDT. Moreover, 47 days were required to obtain ten times the initial tumor volume after mTHPC-EVs/PDT compared to 30 days for liposomal mTHPC. In conclusion, compared to Foslip®, mTHPC-EVs improved mTHPC biodistribution and PDT efficacy in vivo. We deduced that a major determinant factor for the improved in vivo PDT efficacy is the deep mTHPC intratumor penetration.


1991 ◽  
Vol 34 (7) ◽  
pp. 2126-2133 ◽  
Author(s):  
Alan R. Morgan ◽  
Greta M. Garbo ◽  
Rick W. Keck ◽  
Steven H. Selman ◽  
Dimitris Skalkos

Sign in / Sign up

Export Citation Format

Share Document